The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Liver Diseases Therapeutics Market By 2030 Starting From Its 2026 Size?
The liver diseases therapeutics market size has demonstrated strong growth in recent years. It is projected to increase from $15.18 billion in 2025 to $16.66 billion in 2026, at a compound annual growth rate (CAGR) of 9.8%. This historic period’s expansion can be ascribed to several factors, including the high prevalence of viral hepatitis infections, a rising number of alcohol-induced liver disease cases, an early reliance on antiviral and supportive therapies, the limited treatment options available for chronic liver conditions, and the expansion of hospital-based liver care.
The liver diseases therapeutics market size is anticipated to experience substantial growth in the upcoming years, expanding to $24.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This projected growth during the forecast period is primarily fueled by the increasing burden of metabolic liver diseases, the growing adoption of immunosuppressive and targeted therapies, the expansion of liver cancer treatment pipelines, heightened awareness regarding the benefits of early treatment, and increased healthcare spending on chronic liver conditions. Significant trends in the forecast period include an escalating demand for antiviral therapies in hepatitis treatment, a concentrated focus on managing NAFLD and NASH, the increasing use of immunotherapy in liver cancer, the expansion of combination drug therapies, and a rising emphasis on long-term disease management.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7969&type=smp
What Drivers Are Shaping The Future Growth Of The Liver Diseases Therapeutics Market?
The increasing occurrence of liver conditions is projected to drive expansion within the liver disease therapeutics market in the coming years. Liver disease encompasses any ailment impacting the liver, and liver disease therapeutics offer diverse treatments to address these conditions. For illustration, a December 2024 report from the Office for Health Improvement and Disparities, a UK government department, indicated a 3.6% rise in premature deaths from alcoholic liver disease in 2023, climbing to 5,984 from 5,776 in 2022. Consequently, the growing incidence of liver diseases is fueling the development of the liver disease therapeutics market.
Which Segment Categories Define The Liver Diseases Therapeutics Market?
The liver diseases therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer
2) By Treatment: Antiviral, Chemotherapy, Immunosuppressive Agents, Corticosteroids
3) By End User: Hospitals, Ambulatory Surgery Centers
Subsegments:
1) By Hepatitis: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D
2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH), Simple Fatty Liver
3) By Alcohol-Induced: Alcoholic Hepatitis, Alcoholic Cirrhosis
4) By Liver Cancer: Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
How Are Trends Transforming The Liver Diseases Therapeutics Market Landscape?
Leading companies within the liver disease therapeutics market are increasingly concentrating on advanced technologies, such as artificial intelligence, to assist clinicians in the early detection of liver fibrosis in patients during their disease progression. Artificial intelligence in liver disease therapeutics entails the utilization of sophisticated computational algorithms and machine learning techniques to analyze medical data, thereby aiding in prompt detection, accurate diagnosis, and customized treatment strategies for various liver diseases. For instance, in February 2023, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT. This innovative AI-powered tool is designed to forecast liver fibrosis in individuals suffering from chronic liver disease. It functions as a case-finding and cohort mapping instrument, specifically developed to pinpoint patients at risk of chronic liver disease (CLD). The system is secure, intuitive, and straightforward to operate, possessing the ability to examine millions of data entries within seconds to identify patients meeting specific criteria. Additionally, its features encompass comprehensive data analysis, machine learning algorithms, real-time risk stratification, and a user-friendly interface.
Who Are The Top Companies Competing In The Liver Diseases Therapeutics Market?
Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.
Read the full liver diseases therapeutics market report here:
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
Which Geographic Regions Are Influencing Demand In The Liver Diseases Therapeutics Market?
North America was the largest region in the liver diseases therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Liver Diseases Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=7969&type=smp
Browse Through More Reports Similar to the Global Liver Diseases Therapeutics Market 2026, By The Business Research Company
Hepatitis Therapeutics Global Market Report
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Liver Health Supplements Global Market Report
https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report
Fatty Liver Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model